Skip to main content

Table 1 Correlation between patients’ consent to be referred to a DBS center, clinical characteristics and the contents of clarification sessions

From: How to improve patient education on deep brain stimulation in Parkinson’s disease: the CARE Monitor study

  

Group Consent

Group Refusal

 

N = 114 (43.2%)

N = 150 (56.8%)

N

Median

25./75. Quartiles

Median

25./75.Quartiles

p*

Numerical Data

 Age

262

63

53–70

67

60–71

0.002

 Disease duration

245

9

5–12

8

6–12

0.618

 Hoehn & Yahr Stage

250

3

2–3

3

2–3

0.995

 Eligibility for DBS (STIMULUS Score)

260

8

7–9

8

7–9

0.682

 Subjective Impairment

255

7

6–8

7

6–8

0.178

 Number of topics addressed in the clarification talk

264

6

4–9

5

3–9

​0.001

Categorial Data

N

 

%

N

%

p*

Gender

Male

73

64.0

99

66.0

0.795

Female

41

36.0

51

34.0

Occupation

Working

21

18.4

17

11.3

0.362

Retired

79

69.3

118

78.7

Unemployed

13

11.4

14

9.3

Subtype

Akinetic-rigid

45

39.5

33

22.0

​0.008

Tremor dominant

21

18.4

38

25.3

Equivalent

48

42.1

79

52.7

Evaluation of the information material

Helpful

79

89.8

77

69.4

<​0.001

Uncertain

8

9.1

20

18.0

Not helpful

1

1.1

14

12.6

Information source

Media

4

3.5

9

6.0

0.265

Doctor

93

81.6

117

78.0

0.539

Support group

3

2.6

8

5.3

0.360

Others

1

0.9

1

0.7

>0.999

Patient with DBS

3

2.6

0

0.0

0.079

Contents of clarification talk

motor improvement

104

91.2

117

78.0

0.004

quality of life

106

93.0

114

76.0

<​0.001

side effects of medication

86

75.4

76

50.7

<0.001

optimal time frame

66

57.9

50

33.3

<0.001

expectations

60

52.6

62

41.3

0.081

change of role model in partnership

20

17.5

25

16.7

0.870

patients fears

20

17.5

20

13.3

0.388

evidence of DBS

44

38.6

34

22.7

​0.006

experience with DBS

43

37.7

54

30.0

0.191

complications of DBS surgery

63

55.3

74

49.3

0.385

side effects of DBS

58

50.9

63

42.0

0.171

effects of medication withdrawal

32

28.1

39

26.0

0.780

progression of PD

52

45.6

58

38.7

0.260

others

16

14.0

9

6.0

​0.034

  1. * To analyze the impact of numerical data on patients’ decisions, Mann-Whitney U tests were calculated and the median and 25.-75. quartiles are presented. For categorial variables with more than two categories (subtype and occupation) Chi-Square tests were conducted. For categorial variables with two categories, Fisher's exact tests were conducted. Exact two-tailed p values are presented. A variable with a p value < 0.05 was considered as a potential predictive variable and therefore included in the binary regression analysis.
  2. ‡ In the categories information source and contents of clarification talk more than one option could be reported. Therefore, Fisher's exact tests were calculated for the prevalence or absence of each topic/source and the resulting p values are presented. To clarify the presentation only the number of prevalent cases are shown.
  3. The entries in italicized represent significant p values (lower than 0.05)